Feb 13, 2024 8:00am EST Ensysce Biosciences, Inc. Announces Exercise of Warrants for $4.7 Million Gross Proceeds
Feb 06, 2024 8:00am EST Ensysce Biosciences Selected to Present at American Association of Pain Medicine Annual Conference
Jan 31, 2024 8:00am EST Ensysce Biosciences Announces Positive End of Phase 2 Meeting with FDA for PF614 to Treat Severe Pain
Jan 25, 2024 8:00am EST Ensysce Biosciences to Present Groundbreaking Oral Overdose Protection for Opioids at the 5th Annual NIH HEAL Meeting
Jan 23, 2024 8:00am EST Ensysce Biosciences Announces FDA Breakthrough Therapy Designation Granted for PF614-MPAR
Dec 19, 2023 4:15pm EST Ensysce Biosciences Postpones Special Meeting of Stockholders to December 29, 2023
Dec 11, 2023 9:00am EST Ensysce Biosciences Discusses TAAP and MPAR(R) Applications and OncoZenge Partnership with The Stock Day Podcast
Nov 29, 2023 8:05am EST Ensysce Biosciences Announces Completion of $1.7 Million Convertible Note Financing